CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled,
parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD)
of CSL312 in subjects with idiopathic pulmonary fibrosis (IPF).